Kumar Suresh
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$5.2MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $5.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 16, 2025 | NIH | SBIR Phase I Ubiquitin pathway modulators as novel antituberculosis drugs | $302K | PROGENRA INC |
| Sep 19, 2024 | NIH | SBIR Phase I Ubiquitin pathway modulators for treating pancreatitis | $270K | PROGENRA INC |
| Sep 1, 2022 | NIH | SBIR Phase I Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis | $255K | PROGENRA INC |
| Apr 1, 2022 | NIH | SBIR Phase I Parkin activators for cardioprotective therapies | $297K | PROGENRA INC |
| Mar 30, 2022 | NIH | SBIR Phase I Parkin activators for cardioprotective therapies | $297K | PROGENRA INC |
| Aug 5, 2020 | NIH | SBIR Phase I Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs) | $297K | PROGENRA INC |
| Jul 9, 2020 | NIH | SBIR Phase I Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs) | $297K | PROGENRA INC |
| Aug 30, 2019 | NIH | SBIR Phase I Ubiquitin E3 ligase activators for treatment of psoriasis | $224K | PROGENRA INC |
| May 18, 2018 | NIH | SBIR Phase II Small molecule Parkin activators to treat Alzheimer's Disease | $643K | PROGENRA INC |
| Apr 27, 2018 | NIH | SBIR Phase I Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus | $223K | PROGENRA INC |
| Dec 22, 2017 | NIH | SBIR Phase II Ubiquitin pathway inhibitors for treatment of asthma | $636K | PROGENRA INC |
| Aug 29, 2017 | NIH | SBIR Phase I Small molecule ubiquitin ligase modulators for immunotherapy of cancer | $225K | PROGENRA INC |
| Jan 10, 2017 | NIH | SBIR Phase II Ubiquitin pathway inhibitors for treatment of asthma | $757K | PROGENRA INC |
| Jul 5, 2016 | NIH | SBIR Phase I Novel ubiquitin protease inhibitor for treating asthma | $206K | PROGENRA INC |
| Jun 9, 2015 | NIH | SBIR Phase I Novel E3 ligase inhibitors for treatment of neurodegenerative disease | $225K | PROGENRA INC |
Peer ranks
Federal funding#261
Awards as PI#46
Patents#273
Companies
- PROGENRA INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.